Despite industry rhetoric, healthcare technology development overwhelmingly prioritizes physicians over patients. This creates a significant gap, as the ultimate end-user's needs are often an afterthought in solution design.

Dr. Wachter warns that unless payment models change, AI will be used to maximize revenue, not lower costs. If the system rewards doing more or using more expensive treatments, AI decision support will guide clinicians toward those choices, potentially inflating the overall cost of care despite efficiency gains.

The requirement for prescriptions for many safe drugs stems from a paternalistic medical culture that distrusts patients, not from genuine safety concerns. This drives up costs and creates unnecessary barriers, similar to how the establishment initially resisted home pregnancy and COVID tests.

The conviction of an ADHD startup founder for over-prescribing Adderall illustrates the danger of optimizing healthcare for conversions. It proves that a doctor's assessment and incentive for quality care is a critical patient safety feature, not a bug to be removed by tech.

Eli Lilly and Novo Nordisk's DTC programs for weight loss drugs give employers an alternative to point employees towards, providing cover to drop expensive insurance coverage and potentially reducing access for patients who rely on it.

Pharmaceutical companies invest in creating high-quality, patient-centric educational documents. However, these resources often fail to reach patients because physicians are hesitant to distribute materials bearing a corporate logo, creating a "last-mile" delivery problem for crucial information.

The emergence of low-cost, compounded versions of GLP-1 drugs from telehealth companies like Hims is creating significant pricing pressure on market leaders Novo Nordisk and Eli Lilly. This dynamic has pushed the pharma giants toward direct-to-consumer models with lower prices to compete.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

Direct-to-consumer telehealth companies like Hims achieve rapid growth via a vertically integrated model of marketing, medical groups, and pharmacies. This structure allows them to generate revenue from selling medicines, a more scalable business than relying on fees from the practice of medicine alone.